Literature DB >> 16416264

Death of neuronal clusters contributes to variance of age at onset in Huntington's disease.

Branka Cajavec1, Hanspeter Herzel, Samuel Bernard.   

Abstract

Huntington's disease (HD) is a fatal neurodegenerative disease caused by an expanded polyglutamine (polyQ) repeat in the protein huntingtin. Due to selective neuronal loss in the cortex and striatum, HD patients develop various movement disturbances, psychological changes, and dementia. Symptoms usually appear in individuals between 30 and 50 years of age. The principal cause of variability of age at onset (AO) is the length of the polyQ repeat. Several additional genetic factors contributing to the variance have been identified. At least 35% of the variance, however, remains unexplained. Using a stochastic model, we show that the pattern of cell death of striatal neurons might contribute up to 20% of variance of AO.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16416264     DOI: 10.1007/s10048-005-0025-x

Source DB:  PubMed          Journal:  Neurogenetics        ISSN: 1364-6745            Impact factor:   2.660


  25 in total

1.  Familial influence on age of onset among siblings with Huntington disease.

Authors:  A Rosenblatt; R R Brinkman; K Y Liang; E W Almqvist; R L Margolis; C Y Huang; M Sherr; M L Franz; M H Abbott; M R Hayden; C A Ross
Journal:  Am J Med Genet       Date:  2001-07-08

2.  Cause of neural death in neurodegenerative diseases attributable to expansion of glutamine repeats.

Authors:  M F Perutz; A H Windle
Journal:  Nature       Date:  2001-07-12       Impact factor: 49.962

3.  Genotypes at the GluR6 kainate receptor locus are associated with variation in the age of onset of Huntington disease.

Authors:  D C Rubinsztein; J Leggo; M Chiano; A Dodge; G Norbury; E Rosser; D Craufurd
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

4.  Huntington's disease progression. PET and clinical observations.

Authors:  T C Andrews; R A Weeks; N Turjanski; R N Gunn; L H Watkins; B Sahakian; J R Hodges; A E Rosser; N W Wood; D J Brooks
Journal:  Brain       Date:  1999-12       Impact factor: 13.501

5.  Trinucleotide repeat length and progression of illness in Huntington's disease.

Authors:  K Kieburtz; M MacDonald; C Shih; A Feigin; K Steinberg; K Bordwell; C Zimmerman; J Srinidhi; J Sotack; J Gusella
Journal:  J Med Genet       Date:  1994-11       Impact factor: 6.318

6.  Striatal volume loss in HD as measured by MRI and the influence of CAG repeat.

Authors:  H D Rosas; J Goodman; Y I Chen; B G Jenkins; D N Kennedy; N Makris; M Patti; L J Seidman; M F Beal; W J Koroshetz
Journal:  Neurology       Date:  2001-09-25       Impact factor: 9.910

7.  Family and molecular data for a fine analysis of age at onset in Huntington disease.

Authors:  F Squitieri; G Sabbadini; P Mandich; C Gellera; E Di Maria; E Bellone; B Castellotti; E Nargi; U de Grazia; M Frontali; A Novelletto
Journal:  Am J Med Genet       Date:  2000-12-11

8.  Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease.

Authors:  S J Augood; R L Faull; P C Emson
Journal:  Ann Neurol       Date:  1997-08       Impact factor: 10.422

9.  The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease.

Authors:  S E Andrew; Y P Goldberg; B Kremer; H Telenius; J Theilmann; S Adam; E Starr; F Squitieri; B Lin; M A Kalchman
Journal:  Nat Genet       Date:  1993-08       Impact factor: 38.330

10.  A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length.

Authors:  D R Langbehn; R R Brinkman; D Falush; J S Paulsen; M R Hayden
Journal:  Clin Genet       Date:  2004-04       Impact factor: 4.438

View more
  3 in total

Review 1.  A cellular perspective on conformational disease: the role of genetic background and proteostasis networks.

Authors:  Tali Gidalevitz; Elise A Kikis; Richard I Morimoto
Journal:  Curr Opin Struct Biol       Date:  2010-01-05       Impact factor: 6.809

2.  microRNA-128a dysregulation in transgenic Huntington's disease monkeys.

Authors:  Jannet Kocerha; Yan Xu; Melinda S Prucha; Dongming Zhao; Anthony W S Chan
Journal:  Mol Brain       Date:  2014-06-13       Impact factor: 4.041

3.  Quantitative connection between polyglutamine aggregation kinetics and neurodegenerative process in patients with Huntington's disease.

Authors:  Keizo Sugaya; Shiro Matsubara
Journal:  Mol Neurodegener       Date:  2012-05-14       Impact factor: 14.195

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.